

Felix C C Ringshausen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1956977/publications.pdf>

Version: 2024-02-01

105
papers

4,362
citations

168829

31
h-index

129628

63
g-index

131
all docs

131
docs citations

131
times ranked

4022
citing authors

#	ARTICLE	IF	CITATIONS
1	Criteria and definitions for the radiological and clinical diagnosis of bronchiectasis in adults for use in clinical trials: international consensus recommendations. <i>Lancet Respiratory Medicine</i> , 2022, 10, 298-306.	5.2	70
2	CFTR modulation with elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis assessed by the β -adrenergic sweat rate assay. <i>Journal of Cystic Fibrosis</i> , 2022, 21, 442-447.	0.3	10
3	Psychometric Validation of the German Translation of the Quality of Life Questionnaire-Bronchiectasis (QOL-B) – Data from the German Bronchiectasis Registry PROGNOSIS. <i>Journal of Clinical Medicine</i> , 2022, 11, 441.	1.0	1
4	Risk Assessment for Patients with Chronic Respiratory Conditions in the Context of the SARS-CoV-2 Pandemic Statement of the German Respiratory Society with the Support of the German Association of Chest Physicians. <i>Respiration</i> , 2022, 101, 307-320.	1.2	5
5	Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on CFTR Function in Patients with Cystic Fibrosis and One or Two Δ F508del Alleles. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 540-549.	2.5	78
6	Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on Lung Clearance Index and Magnetic Resonance Imaging in Patients with Cystic Fibrosis and One or Two Δ F508del Alleles. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 206, 311-320.	2.5	49
7	The disease-specific clinical trial network for primary ciliary dyskinesia: PCD-CTN. <i>ERJ Open Research</i> , 2022, 8, 00139-2022.	1.1	9
8	Management of Drug Toxicity in <i>Mycobacterium avium</i> Complex Pulmonary Disease: An Expert Panel Survey. <i>Clinical Infectious Diseases</i> , 2021, 73, e256-e259.	2.9	16
9	Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More Δ F508del Alleles: Interim Results of an Open-Label Phase 3 Clinical Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 381-385.	2.5	116
10	Efficacy and safety of TOBI Podhaler in <i>Pseudomonas aeruginosa</i> -infected bronchiectasis patients: iBEST study. <i>European Respiratory Journal</i> , 2021, 57, 2001451.	3.1	30
11	The Primary Ciliary Dyskinesia Computed Tomography Score in Adults with Bronchiectasis: A Derivation und Validation Study. <i>Respiration</i> , 2021, 100, 499-509.	1.2	3
12	Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study. <i>Lancet Respiratory Medicine</i> , 2021, 9, 733-746.	5.2	33
13	Pharmacokinetics of Meropenem in People with Cystic Fibrosis – A Proof of Concept Clinical Trial. <i>Antibiotics</i> , 2021, 10, 292.	1.5	1
14	Predictive modeling of nontuberculous mycobacterial pulmonary disease epidemiology using German health claims data. <i>International Journal of Infectious Diseases</i> , 2021, 104, 398-406.	1.5	20
15	Computed Tomography in Adults with Bronchiectasis and Nontuberculous Mycobacterial Pulmonary Disease: Typical Imaging Findings. <i>Journal of Clinical Medicine</i> , 2021, 10, 2736.	1.0	5
16	Anti-IL5 and anti-IL5R α therapy for clinically significant bronchiectasis with eosinophilic endotype: a case series. <i>European Respiratory Journal</i> , 2020, 55, 1901333.	3.1	42
17	A novel NFKBIA variant substituting serine 36 of I κ B α causes immunodeficiency with warts, bronchiectasis and juvenile rheumatoid arthritis in the absence of ectodermal dysplasia. <i>Clinical Immunology</i> , 2020, 210, 108269.	1.4	16
18	Intestinal current measurement and nasal potential difference to make a diagnosis of cases with inconclusive Δ CFTR genetics and sweat test. <i>BMJ Open Respiratory Research</i> , 2020, 7, e000736.	1.2	18

#	ARTICLE	IF	CITATIONS
19	Generation of two hiPSC clones (MHHi019-A, MHHi019-B) from a primary ciliary dyskinesia patient carrying a homozygous deletion in the NME5 gene (c.415delA (p.Ile139Tyrfs*8)). Stem Cell Research, 2020, 48, 101988.	0.3	7
20	Generation of two hiPSC lines (MHHi016-A, MHHi016-B) from a primary ciliary dyskinesia patient carrying a homozygous 5Åbp duplication (c.248_252dup (p.Gly85Cysfs*11)) in exon 1 of the CCNO gene. Stem Cell Research, 2020, 46, 101850.	0.3	4
21	Generation of two human induced pluripotent stem cell lines (MHHi017-A, MHHi017-B) from a patient with primary ciliary dyskinesia carrying a homozygous mutation (c.7915CÀ>ÀT [p.Arg2639*]) in the DNAH5 gene. Stem Cell Research, 2020, 46, 101848.	0.3	4
22	Eradication of Pseudomonas aeruginosa within the baseline dataset of the German Bronchiectasis Registry PROGNOSIS. , 2020, , .		1
23	Airway clearance techniques in patients with bronchiectasis. Data from the EMBARC Registry. , 2020, , .		3
24	Allergic bronchopulmonary aspergillosis as aetiology of bronchiectasis: data from the German bronchiectasis registry PROGNOSIS. , 2020, , .		0
25	Immunodeficiency associated bronchiectasis in the European Bronchiectasis Registry (EMBARC). , 2020, , .		0
26	Efficacy of inhaled dry powder tobramycin (TOBI Podhaler) in P. aeruginosa infected patients with bronchiectasis - iBEST study. , 2020, , .		1
27	Placebo effects in pharmaceutical clinical trials in bronchiectasis: an EMBARC study. , 2020, , .		1
28	Alpha-1 antitrypsin deficiency in patients with bronchiectasis: data from the European Bronchiectasis Registry EMBARC. , 2020, , .		0
29	Increasing bronchiectasis prevalence in Germany, 2009â€“2017: a population-based cohort study. European Respiratory Journal, 2019, 54, 1900499.	3.1	33
30	Pulmonary nocardiosis in Western Europeâ€”Clinical evaluation of 43 patients and population-based estimates of hospitalization rates. International Journal of Infectious Diseases, 2019, 81, 140-148.	1.5	39
31	Recommendations for travelling with bronchiectasis: a joint ELF/EMBARC/ERN-Lung collaboration. ERJ Open Research, 2019, 5, 00113-2019.	1.1	4
32	Economic burden of bronchiectasis in Germany. European Respiratory Journal, 2019, 53, 1802033.	3.1	44
33	Global Epidemiology of NTM Disease (Except Northern America). Respiratory Medicine, 2019, , 163-260.	0.1	8
34	Determinants of survival in the European Bronchiectasis Registry(EMBARC). , 2019, , .		1
35	New isolation of non-tuberculous mycobacteria in patients with bronchiectasis - data from the European Bronchiectasis Registry (EMBARC). , 2019, , .		1
36	Assessment of a Mobile App by Adolescents and Young Adults With Cystic Fibrosis: Pilot Evaluation. JMIR MHealth and UHealth, 2019, 7, e12442.	1.8	15

#	ARTICLE	IF	CITATIONS
37	Risk factors for new <i>P. aeruginosa</i> isolation in bronchiectasis- data from the European Bronchiectasis Registry (EMBARC). , 2019, , .		1
38	Derivation und Validation of a Primary Ciliary Dyskinesia Computed Tomography (PCD-CT) Score in patients with bronchiectasis. , 2019, , .		0
39	GORD/PPI and exacerbations in adults with bronchiectasis. , 2019, , .		0
40	Microbiologic Outcome of Interventions Against Mycobacterium avium Complex Pulmonary Disease. Chest, 2018, 153, 888-921.	0.4	102
41	Cross-infection risk in patients with bronchiectasis: a position statement from the European Bronchiectasis Network (EMBARC), EMBARC/ELF patient advisory group and European Reference Network (ERN-Lung) Bronchiectasis Network. European Respiratory Journal, 2018, 51, 1701937.	3.1	23
42	ERS syllabus for postgraduate training in respiratory infections: a guide for comprehensive training. Breathe, 2018, 14, 269-275.	0.6	1
43	Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by <i>Mycobacterium avium</i> Complex (CONVERT). A Prospective, Open-Label, Randomized Study. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 1559-1569.	2.5	206
44	Chronic Granulomatous Disease First Diagnosed in Adulthood Presenting With Spinal Cord Infection. Frontiers in Immunology, 2018, 9, 1258.	2.2	7
45	The Italian registry of pulmonary non-tuberculous mycobacteria - IRENE: the study protocol. Multidisciplinary Respiratory Medicine, 2018, 13, 33.	0.6	10
46	Why, when and how to investigate primary ciliary dyskinesia in adult patients with bronchiectasis. Multidisciplinary Respiratory Medicine, 2018, 13, 26.	0.6	27
47	Computed tomography in adult patients with primary ciliary dyskinesia: Typical imaging findings. PLoS ONE, 2018, 13, e0191457.	1.1	23
48	Determinants of quality of life in bronchiectasis using the quality of life bronchiectasis (QOL-B) questionnaire: data from the EMBARC registry. , 2018, , .		3
49	The heterogeneity of bronchiectasis patient characteristics, management and outcomes across Europe: Data from the EMBARC registry. , 2018, , .		4
50	Impact of Inflammatory bowel disease in bronchiectasis (IBD-BR) data from the EMBARC registry. , 2018, , .		1
51	Characteristics of patients with pulmonary non-tuberculous Mycobacterial infection in bronchiectasis: Data from the EMBARC registry. , 2018, , .		3
52	Primary ciliary dyskinesia in adults with bronchiectasis: Data from the Embarc registry. , 2018, , .		4
53	Rhinosinusitis is associated with increased symptoms and more frequent exacerbations among patients with bronchiectasis- data from the EMBARC registry. , 2018, , .		1
54	Chest Physiotherapy in patients with Bronchiectasis – what is the current practice in Europe?. , 2018, , .		0

#	ARTICLE	IF	CITATIONS
55	Validity of COPD diagnosis in Bronchiectasis patients: data from the EMBARC registry. , 2018, , .		0
56	Late Breaking Abstract - Use of mepolizumab in bronchiectasis with underlying eosinophilic condition. , 2018, , .		0
57	Quality of life is associated with increased symptom burden and markers of disease severity: data from the German Bronchiectasis Registry PROGNOSIS. , 2018, , .		0
58	Burden of non-tuberculous mycobacterial pulmonary disease in Germany. European Respiratory Journal, 2017, 49, 1602109.	3.1	100
59	Microbiological and Clinical Outcomes of Treating Non- Mycobacterium Avium Complex Nontuberculous Mycobacterial Pulmonary Disease. Chest, 2017, 152, 120-142.	0.4	137
60	Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research. European Respiratory Journal, 2017, 49, 1700051.	3.1	253
61	European Respiratory Society guidelines for the management of adult bronchiectasis. European Respiratory Journal, 2017, 50, 1700629.	3.1	788
62	Nasal Nitric Oxide Measurement and a Modified PICADAR Score for the Screening of Primary Ciliary Dyskinesia in Adults with Bronchiectasis. Pneumologie, 2017, 71, 543-548.	0.1	17
63	Tezacaftorâ€“lvacaftor in Residual-Function Heterozygotes with Cystic Fibrosis. New England Journal of Medicine, 2017, 377, 2024-2035.	13.9	412
64	Chest physiotherapy in European patients with bronchiectasis: Data from the EMBARC registry. , 2017, , .		3
65	PROGNOSIS - the German Bronchiectasis Registry: first results. , 2017, , .		0
66	Value of CT in patients with bronchiectasis for detection of PCD. , 2017, , .		0
67	The association between gastro-oesophageal reflux and exacerbations of bronchiectasis: data from the EMBARC registry. , 2017, , .		0
68	Prevalence of Nontuberculous Mycobacterial Pulmonary Disease, Germany, 2009â€“2014. Emerging Infectious Diseases, 2016, 22, 1102-1105.	2.0	104
69	Lung transplantation for non-cystic fibrosis bronchiectasis. Respiratory Medicine, 2016, 115, 60-65.	1.3	26
70	Why do some adults with PIMZ Î±1-antitrypsin develop bronchiectasis?. ERJ Open Research, 2016, 2, 00021-2016.	1.1	5
71	Research priorities in bronchiectasis: a consensus statement from the EMBARC Clinical Research Collaboration. European Respiratory Journal, 2016, 48, 632-647.	3.1	170
72	The EMBARC European Bronchiectasis Registry: protocol for an international observational study. ERJ Open Research, 2016, 2, 00081-2015.	1.1	133

#	ARTICLE	IF	CITATIONS
73	Should all adult cystic fibrosis patients with repeated nontuberculous mycobacteria cultures receive specific treatment? A 10-year caseâ€“control study. <i>European Respiratory Journal</i> , 2016, 47, 1575-1577.	3.1	8
74	Nasal potential difference of carriers of the W493R ENaC variant with non-cystic fibrosis bronchiectasis. <i>European Respiratory Journal</i> , 2016, 47, 322-324.	3.1	8
75	Young adult with inherited PiMZ alpha-1-antitrypsin deficiency (A1ATD)-related bronchiectasis: characteristic of blood neutrophils and A1AT protein. , 2016, , .		0
76	Nasal nitric oxide measurement and a score of key clinical features for the screening of primary ciliary dyskinesia in patients with non-cystic fibrosis bronchiectasis. , 2016, , .		0
77	False-negative interferon-Î³ release assay results in active tuberculosis: a TBNET study. <i>European Respiratory Journal</i> , 2015, 45, 279-283.	3.1	36
78	Risk Assessment of Tuberculosis in Contacts by IFN-Î³ Release Assays. A Tuberculosis Network European Trials Group Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 191, 1176-1184.	2.5	101
79	Bronchiectasis in Germany: a population-based estimation of disease prevalence. <i>European Respiratory Journal</i> , 2015, 46, 1805-1807.	3.1	122
80	Heterogeneity in bronchiectasis service provision in Europe: Baseline data from the European bronchiectasis registry (EMBARC). , 2015, , .		1
81	Lung transplantation for Non- Cystic fibrosis bronchiectasis: A single centre retrospective analysis of 34 patients. , 2015, , .		0
82	Research priorities in bronchiectasis: A consensus from the European multicentre bronchiectasis audit and research collaboration (EMBARC) study group. , 2015, , .		0
83	Six simple questions contra the delay. <i>European Respiratory Journal</i> , 2014, 43, 10-11.	3.1	0
84	Course and treatment of chronic hepatitis E virus infection in lung transplant recipients. <i>Transplant Infectious Disease</i> , 2014, 16, 333-339.	0.7	36
85	Tuberculosis in healthcare workers â€“ a narrative review from a German perspective. <i>Journal of Occupational Medicine and Toxicology</i> , 2014, 9, 9.	0.9	36
86	Occupational Screening for Tuberculosis and the Use of a Borderline Zone for Interpretation of the IGRA in German Healthcare Workers. <i>PLoS ONE</i> , 2014, 9, e115322.	1.1	45
87	Burden and trends of hospitalisations associated with pulmonary non-tuberculous mycobacterial infections in Germany, 2005â€“2011. <i>BMC Infectious Diseases</i> , 2013, 13, 231.	1.3	63
88	IFN-Î³ release assay versus tuberculin skin test for monitoring TB infection in healthcare workers. <i>Expert Review of Anti-Infective Therapy</i> , 2013, 11, 37-48.	2.0	51
89	Prevention and treatment of exacerbations of non-CF bronchiectasis. , 2013, , 127-136.		2
90	Bronchiectasis-Associated Hospitalizations in Germany, 2005â€“2011: A Population-Based Study of Disease Burden and Trends. <i>PLoS ONE</i> , 2013, 8, e71109.	1.1	126

#	ARTICLE	IF	CITATIONS
91	Frequent Detection of Latent Tuberculosis Infection among Aged Underground Hard Coal Miners in the Absence of Recent Tuberculosis Exposure. PLoS ONE, 2013, 8, e82005.	1.1	9
92	Serial IGRA testing of trainees in the healthcare sector in a country with low incidence for tuberculosis - a prospective cohort study. GMS Hygiene and Infection Control, 2013, 8, Doc17.	0.2	14
93	Interferon-gamma release assays for the tuberculosis serial testing of health care workers: a systematic review. Journal of Occupational Medicine and Toxicology, 2012, 7, 6.	0.9	73
94	TB as an occupational disease. , 2012, , 219-229.		2
95	Specificity of a whole blood IGRA in German nursing students. BMC Infectious Diseases, 2011, 11, 245.	1.3	16
96	Screening for tuberculosis and prediction of disease in Portuguese healthcare workers. Journal of Occupational Medicine and Toxicology, 2011, 6, 19.	0.9	39
97	Within-Subject Variability of Mycobacterium tuberculosis-Specific Gamma Interferon Responses in German Health Care Workers. Vaccine Journal, 2011, 18, 1176-1182.	3.2	65
98	Predictors of persistently positive Mycobacterium-tuberculosis-specific interferon-gamma responses in the serial testing of health care workers. BMC Infectious Diseases, 2010, 10, 220.	1.3	73
99	Serial testing with an interferon- γ release assay in German healthcare workers. GMS Krankenhaushygiene Interdisziplinär, 2010, 5, .	0.3	23
100	Frequency and clinical relevance of human bocavirus infection in acute exacerbations of chronic obstructive pulmonary disease. International Journal of COPD, 2009, 4, 111.	0.9	16
101	A fatal case of spinal tuberculosis mistaken for metastatic lung cancer: recalling ancient Pott's disease. Annals of Clinical Microbiology and Antimicrobials, 2009, 8, 32.	1.7	27
102	In-hospital contact investigation among health care workers after exposure to smear-negative tuberculosis. Journal of Occupational Medicine and Toxicology, 2009, 4, 11.	0.9	28
103	No evidence for WU polyomavirus infection in chronic obstructive pulmonary disease. Infectious Agents and Cancer, 2009, 4, 12.	1.2	3
104	Inhaled antibiotics in chronic airway infections. , 0, , 57-79.		0
105	Bronchiektasen: Vielfach unterschätzt. , 0, , .		0